MedTrace Logo

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

NCT00415285 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-02-13

No results posted yet for this study

Summary

The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Docetaxel

DRUG

Capecitabine

DRUG

Docetaxel/Capecitabine

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Georgia Center for Oncology Research & Education

    lead OTHER

Principal Investigators

  • Ruth O'Regan, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00415285 on ClinicalTrials.gov